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Uncovering the transcriptomic and
epigenomic landscape of nicotinic receptor
genes in non-neuronal tissues
Bo Zhang1,2* , Pamela Madden3, Junchen Gu2, Xiaoyun Xing2, Savita Sankar1, Jennifer Flynn2, Kristen Kroll1
and Ting Wang2*
Abstract
Background: Nicotinic acetylcholine receptors (nAChRs) play an important role in cellular physiology and human
nicotine dependence, and are closely associated with many human diseases including cancer. For example, previous
studies suggest that nAChRs can re-wire gene regulatory networks in lung cancer cell lines. However, the tissue specificity
of nAChRs genes and their regulation remain unexplored.
Result: In this study, we integrated data from multiple large genomic consortiums, including ENCODE, Roadmap
Epigenomics, GTEx, and FANTOM, to define the transcriptomic and epigenomic landscape of all nicotinic receptor genes
across many different human tissues and cell types. We found that many important nAChRs, including CHRNA3, CHRNA4,
CHRNA5, and CHRNB4, exhibited strong non-neuronal tissue-specific expression patterns. CHRNA3, CHRNA5, and
CHRNB4 were highly expressed in human colon and small intestine, and CHRNA4 was highly expressed in human
liver. By comparing the epigenetic marks of CHRNA4 in human liver and hippocampus, we identified a novel liver-
specific transcription start site (TSS) of CHRNA4. We further demonstrated that CHRNA4 was specifically transcribed
in hepatocytes but not transcribed in hepatic sinusoids and stellate cells, and that transcription factors HNF4A and
RXRA were likely upstream regulators of CHRNA4. Our findings suggest that CHRNA4 has distinct transcriptional
regulatory mechanisms in human liver and brain, and that this tissue-specific expression pattern is evolutionarily
conserved in mouse. Finally, we found that liver-specific CHRNA4 transcription was highly correlated with genes
involved in the nicotine metabolism, including CYP2A6, UGT2B7, and FMO3. These genes were significantly down-
regulated in liver cancer patients, whereas CHRNA4 is also significantly down-regulated in cancer-matched normal livers.
Conclusions: Our results suggest important non-neuronally expressed nicotinic acetylcholine receptors in the human
body. These non-neuronal expression patterns are highly tissue-specific, and are epigenetically conserved during
evolution in the context of non-conserved DNA sequence.
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Background
Tobacco dependence (mainly through cigarette smoking)
is a major global health problem and is a main cause of
cancer and cancer-related death throughout the world.
Nicotine, the biologically active substance in tobacco, pro-
motes the addiction of smoking behaviors through activa-
tion of nicotinic acetylcholine receptors (nAChRs) [1].
These nAChRs typically combine to form fast, ionotropic
cationic nicotinic receptor channels. Pentameric nAChRs
usually consist of five subunits, with an overall molecular
weight of 290 kDa. nAChRs subunits are broadly classified
into two subtypes: muscle-type nicotinic receptors, includ-
ing α1, β1, γ, δ, and ε subunits, and neuronal-type nico-
tinic receptors, including α2 − α10 and β2 − β4 subunits.
Neuronal-type nicotinic receptors are usually found in the
brain, and exhibit some similarities with GABAa receptors
and glycine receptors [1]. In human brain, the α4 and β2
subunits are predominantly expressed and form penta-
meric (α4)3(β2)2 and (α4)2(β2)3 nAChRs. Other nAChR
subunits, including α3, α5 α7, β3, and β4 are also
expressed in human brain, usually forming homomeric
and heteromeric receptors [2].
Neuronal-type nAChRs are generally believed to func-
tion in the brain and contribute to nicotine dependence
through reward pathways [3]. Interestingly, previous
studies reported that several neuronal-type nAChRs are
also expressed in lung cancer cells and intestinal epithe-
lium cells [4–7]. However, the overall expression pattern
of nAChRs in different human tissues is largely un-
known. To gain the knowledge of tissue - specific regu-
lation of nAChRs, we took advantage of resources
generated by several large genomic consortiums that
aim to functionally annotate the human genome, includ-
ing the ENCODE project [8], Roadmap Human Epige-
nomics project [9], FANTOM project [10], and GTEx
project [11]. By comparing and combining extensive
genomic datasets produced by these consortiums, we
were able to define a comprehensive transcriptomic and
epigenomic landscape of nAChR genes and investigate
the regulatory mechanisms governing activities of these
important genes.
Surprisingly, our investigation revealed that many
neuronal-type nicotinic receptor subunits were highly
expressed in non-neuronal tissues. In particular, we
identified liver-specific expression of CHRNA4, and
colon- and intestine-specific expression of CHRNA3,
CHRNA5, and CHRNB4. These tissue-specific expres-
sion patterns of nAChRs were consistent with tissue-
specific epigenetic patterns of these genes. Additionally,
we discovered a novel alternative promoter of CHRNA4
in human liver, through which transcription factors
HNF4A and RXRA could directly regulate CHRNA4
expression in hepatocytes. Despite the lack of DNA
sequence conservation at the liver-specific promoter of
CHRNA4 between rodents and hominoids, the liver-
specific expression and regulatory mechanism of
CHRNA4 seem to be evolutionarily conserved between
human and mouse liver. These results suggest a genetic-
ally dynamic but epigenetically conserved evolutionary
history of CHRNA4.
Results
Tissue-specific expression pattern of human nAChRs
To understand the expression pattern of nAChR subunits
in human, we examined the mRNA expression levels of
13 nAChRs genes that encode 9 alpha-subunits and 4
beta-subunits. By analyzing mRNA-sequencing data from
27 different human tissues and cell types generated by the
Roadmap Epigenomes project [9], we found that nAChRs
varied widely in their expression in a tissue-dependent
manner. For example, CHRNB1 was found to be highly
expressed across multiple tissues (Fig. 1a). Surprisingly,
while CHRNB2, the beta-subunit of α4β2-containing nico-
tinic receptors, was found to only be highly expressed in
brain tissues, CHRNA4, the most abundant nAChR alpha-
subunit in human brain [2], was highly expressed in hu-
man adult liver in addition to being highly expressed in
brain (Fig. 1). This tissue-specific expression pattern was
validated in an independent cohort based on the
Genotype-Tissue Expression project (GTEx) [11] (Fig. 1b).
The CHRNA3-CHRNA5-CHRNB4 loci (chr15-q25.1) is
the hotspot for genetic variants that are associated with
heavy smoking and nicotine dependence [12–14]. While
these genes exhibit expected expression in the brain, we
found much higher expression levels of CHRNA3,
CHRNA5, and CHRNB4 in colon and small intestine
than in brain tissues. This expression pattern was also
recapitulated by the GTEx datasets (Fig. 1b).
Epigenetic profile predicts novel liver-specific alternative
promoter for CHRNA4
Tissue-specific epigenetic profiles of a gene are strong
predictors of tissue-specific gene activity. Active histone
modifications (for example, H3K4me1, H3K4me3, and
H3K27ac) and DNA hypomethylation in promoter re-
gions are hallmarks of active genes [8, 9, 15]. To under-
stand the high expression of neuronal-type nAChRs in
human non-neuronal tissues, we examined the epigen-
etic landscape around CHRNA3, CHRNA4, CHRNA5,
CHRNB2, and CHRNB4 in human liver, hippocampus,
CD34 hematopoietic stem cells, colon, and lung tissues
using the WashU Epigenome browser [16, 17]. We
found that tissue-specific expression of nAChRs was
strongly associated with the tissue-specific active epigen-
etic marks around the gene promoter (Additional file 1:
Figure S1). In human hippocampus, we detected strong
H3K4me3 and H3K27ac signals around known tran-
scription start sites (TSS) of CHRNA3, CHRNA5,
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CHRNB2, CHRNB4, and CHRNA4 (Additional file 2:
Figure. S2). Strikingly, in liver we detected very strong
H3K4me3 and H3K27ac signals at 3.9 kb upstream of
the known RefSeq TSS (Fig. 2a). This stunning promoter
signature predicted a liver-specific, alternative promoter
and/or transcription start site for CHRNA4.
Our prediction was confirmed using the Cap Analysis
Gene Expression sequencing (CAGE-seq) data from the
FANTOM5 project [10]. CAGE-seq identifies gene tran-
scription start sites by sequencing the 5′ capped ends of
mRNAs [18]. We found that the CAGE signal from hu-
man liver was only presented at −3.9 kb upstream
(chr20: 61,996,626–61,996,696) of the canonical TSS. In
contrast, CAGE signal from brain was located around
the known canonical CHRNA4 RefSeq TSS (chr20:
61,992,747–61,992,748) (Fig. 2a). As a control, we exam-
ined the histone modifications and CAGE signal for the
CHRNA4 gene in human CD34+ hematopoietic stem
cells (CD34-HSCs), where the gene is known to be silent
(Fig. 1a). We did not observe enrichment of active his-
tone modification marker (H3K27ac) at either brain-
specific or liver-specific promoter regions of CHRNA4 in
HSCs, nor did we observe CAGE signal in these regions
(Fig. 2a). We also noticed that the single nucleotide
polymorphism (SNPs) around CHRNA4 were not associ-
ated with CHRNA4 expression level in brain hippocam-
pus, but 4 SNPs were strongly associated with CHRNA4
expression level in human liver (Fig. 2a, processed ex-
pression quantitative trait loci (eQTL) data was down-
loaded from GTEx Project).
We also examined the DNA methylation level of both
brain-specific and liver-specific CHRNA4 promoter re-
gions (+/−500 bp of the TSS). The liver-specific
CHRNA4 promoter was significantly hypomethylated in
human liver and hypermethylated in both brain and
CD34-HSCs (Fig. 2b), while the brain-specific promoter
was hypermethylated in liver and hypomethylated in the
hippocampus and CD34-HSCs (Fig. 2b). Additionally,
we validated the expression level of CHRNA4 using q
RT-PCR, and confirmed that the expression of CHRNA4
is about five-fold higher in human liver than it is in hu-
man brain, and CHRNA4 is not expressed in B cell
lymphocyte (Fig. 2c). Taken together, our results reveal a
distinctive promoter usage of the CHRNA4 gene in hu-
man liver and brain, highlighting a novel tissue-specific
regulatory mechanism.
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Fig. 1 Tissue-specific expression patterns of nicotinic acetylcholine receptors (nAChRs). a Heat map view of nAChRs expression patterns in 27
human tissue/cell types. Color scale indicates the expression level (RPKM) measured by RNA-seq from the Human Roadmap Epigenome project. b
Expression level of CHRNA4, CHRNB2, CHRNA3, CHRNA5, CHRNAB4, and CHRNB1 in human brain, liver, colon, small intestine, and lung tissue. Y-axis
indicates expression level (RPKM) measured by RNA-seq data from the GTEx project. Student t-test was performed to detect statistical significance
Zhang et al. BMC Genomics  (2017) 18:439 Page 3 of 12
Conserved expression and epigenetic patterns of Chrna4
in mouse
Nicotinic acetylcholine receptors play important roles in
the central nervous system, and are highly conserved
from Drosophila to vertebrates [19]. We next deter-
mined if the unexpected liver-specific expression of
CHRNA4 observed in human was an evolutionarily con-
served phenomenon. To this end we took advantage of
the data resources produced by the mouseENCODE
consortium and FANTOM5 [10, 20] by integrating gene
expression data, epigenomic data, and RNA polymerase
II (Pol-2) ChIP-seq data, with CAGE-seq data from
mouse brain and liver. We found that the epigenetic
landscape between human and mouse is highly con-
served in a tissue-specific manner surrounding the
CHRNA4 /chrna4 gene in human and mouse, respect-
ively. In mouse liver, active epigenetic modifications, in-
cluding the H3K27ac signal, PoI-2 ChIP-seq signals, and
DNaseI hypersensitivity signal, were highly enriched in a
region ~4.8 kb upstream of the RefSeq annotated
Chrna4 TSS. In contrast, in mouse brain, the active
epigenetic modifications were depleted in this region,
but enriched around the canonical promoter (Additional
file 2: Figure S2A). CAGE-seq data also support the al-
terative TSS usages between brain and liver (Additional
file 2: Figure S2A, Fig. 4b). Specifically, the CAGE-seq
signals were not found in hepatic sinusoids and stellate
cells but was only presented in hepatocytes (Fig. 4b).
We further confirmed the higher expression of Chrna4
in mouse liver than in brain with RT-PCR (Additional
file 2: Fig. S2B). These data strongly suggest that there
exists a novel but evolutional conserved mechanism to
regulate tissue-specific activities of CHRNA4/Chrna4 in
human and mouse, and that this neuronal-type nAChR
might play a conserved and uncharacterized role in liver.
Further, we checked the DNA sequence conservation
of the liver-specific CHRNA4 and Chrna4 promoters.
We found that the orthologous region of the human
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liver-specific CHRNA4 TSS is conserved only in homin-
oid monkeys, and is absent in many other monkeys
(Rhesus, Baboon, macaque, and marmoset) and rodents
(Fig. 3a). Conversely, the orthologous region of the
mouse liver-specific Chrna4 TSS is highly conserved
among rodents, primates and other mammals (Fig. 3b).
In the human genome, we found a highly enriched
H3K4me1 signal in the orthologous region of the mouse
liver-specific Chrna4 TSS, which is located ~2 kb up-
stream the human liver-specific CHRNA4 TSS (Fig. 2a,
Fig. 4b). Such evidence suggests that a ‘turn-over’ event
may have occurred during primate evolution, and may
also suggest that the ‘evolutionarily conserved’ liver-
specific expression of CHRNA4/Chrna4 evolved inde-
pendently in hominoids and rodent animals.
HNF4A and RXRA may be involved in liver-specific
CHRNA4 expression
To understand the liver-specific regulatory mechanism
of CHRNA4, we examined the transcription factor
binding events around the CHRNA4 promoter region.
Over 20 different transcription factors were found to
bind to the 10 kb region surrounding the CHRNA4
promoter, as determined by the ENCODE consortium
(Additional file 3: Figure S3). Considering the liver-
specific expression pattern of CHRNA4, we reasoned
that the upstream transcription factors of CHRNA4
should have a similar liver-specific expression pattern.
After examining the expression patterns of 22 tran-
scription factors that had binding sites near the
CHRNA4 promoter across 31 major human tissues, we
identified HNF4A and RXRA as highly expressed in
human livers (Fig. 4a) and with binding sites in the
vicinity of the CHRNA4 promoter. We also analyzed
ChIP-seq data for Hnf4a and Rxra in mouse, and found
that Hnf4a and Rxra directly bind to the promoter re-
gion of Chrna4. Furthermore, an Rxra ChIP-seq peak
directly overlapped with the mouse liver-specific TSS
(Fig. 4b). These data indicate that HNF4A /Hnf4a and
RXRA/Rxra could be important TFs regulating the
liver-specific expression of CHRNA4 / Chrna4 in both
human and mouse, providing a potential mechanistic
explanation behind the observed ‘conserved expression
pattern’ of CHRNA4/Chrna4 between rodents and pri-
mates. We identified 4 SNPs to be significantly associ-
ated with expression of CHRNA4 in human liver
(eQTL), and all 4 SNPs were located within a liver -
specific regulatory element (Figs. 2a and 4b). Two of
the SNPs, rs755203 and rs3810471, were directly under
RXRA and HNF4A ChIP-seq peaks, although they did
not overlap with predicted RXRA or HNF4A binding
motifs. Three SNPs, rs6089899, rs755203, and
rs3810471, were predicted to influence binding affin-
ities of several transcription factors including Krüppel-
Like Factor (KLF) family members (Table 1).
Liver-specific CHRNA4 expression is associated with
nicotine metabolism pathway
To understand the potential roles of CHRNA4 in the
liver, we investigated the enriched functions of genes co-
expressed with CHRNA4 in 119 normal human liver
samples (GTEx V6). We found 705 genes were signifi-
cantly and positively correlated with CHRNA4 expres-
sion, whereas another 380 genes were significantly and
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Fig. 3 Evolutionary dynamics of the CHRNA4 liver-specific promoter. a WashU EpiGenome Browser views of the conserved CHRNA4 liver-specific
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negatively correlated (Additional file 4: Figure S4,
Additional file 5: Table S1). By using Ingenuity Pathway
Analysis, we found that genes significantly positively cor-
related with CHRNA4 were highly enriched in several
metabolic pathways, specifically in nicotine degradation
(Fig. 5a, Additional file 6: Fig. S5). We further examined
the expression level of important nicotine metabolism
genes, and found expression of CYP2A6, UGT2B7, and
FMO3 were significantly correlated with CHRNA4’s ex-
pression in human liver (Fig. 5b). UGT1A6 exhibited
anti-correlation but the correlation was less significant
(Fig. 5b) and the expression level was relatively low
(Additional file 7: Figure S6).
Smoking is generally believed to be a risk factor for
liver cancer [21], we further examined the expression of
CHRNA4 and nicotine metabolism - related genes in
liver cancer samples by using TCGA liver hepatocellular
carcinoma transcriptome data. With the exception of
UGT1A6, all other genes were significantly less
expressed in liver hepatocellular carcinoma as compared
to normal liver samples (Fig. 5c). Furthermore, nicotine
metabolism - related genes CYP2A6, FMO3, and
UGT2B7 were expressed at a similar level in benign
cancer-matched normal livers as in normal liver con-
trols. However, CHRNA4 was significantly down-
regulated in cancer-matched normal livers (Fig. 5c).
Discussion
Nicotine is a lipophilic compound present at high levels
in tobacco leaves, and can be easily absorbed in the
bloodstream after smoking or chewing tobacco leaves.
Nicotine can rapidly cross the blood-brain barrier and
bind with high affinity to neuronal nicotinic acetylcho-
line receptors (nAChRs). nAChR activation excites target
cells and mediates fast synaptic transmissions in autono-
mous ganglionic neurons in the brain [22, 23]. In human
brain, CHRNA4 and CHRNB2, in the form of (α4)3(β2)2,
are the most abundant subunits of pentameric neuronal
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The Y-axis indicates expression level (RPKM) measured by RNA-seq data from the GTEx project. The tissues are ranked by median expression of HNF4A and
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nicotinic receptors; however, other nAChR subunits (α3,
α5, α7, β2, β3, β4) also function as important compo-
nents of homomeric/heteromeric receptor complexes
[24]. All of these genes are associated with human smok-
ing behaviors and nicotine addiction [6, 7, 25–33].
In an effort to define the tissue-specific epigenomic
and transcriptomic landscape of nAChR genes, we dis-
covered that CHRNA4 was highly expressed in human
liver. Additionally, CHRNA3, CHRNA5, and CHRNB4
were highly expressed in colon and kidney. Expression
of these neuronal-type nAChRs in non-neuronal tissues
was strongly correlated with their tissue-specific epige-
nomic patterns. Further investigation led us to the dis-
covery of a novel alternative promoter that regulates
CHRNA4 transcription specifically in liver. Importantly,
this regulatory mechanism is evolutionarily conserved,
as we confirmed an almost identical pattern in mouse.
Our analysis further suggests that transcription factors
HNF4A and RXRA may play a role as the upstream reg-
ulators of CHRNA4, potentially orchestrating the co-
regulation of CHRNA4 and CYP2A6, a key gene involved
in nicotine metabolism [34]. Thus, our results establish
correlated regulation as well as deregulation between
CHRNA4, a gene that encodes a nicotine acetylcholine
receptor, and genes involved in nicotine metabolism, in
the context of normal liver and liver cancer, opening
doors for questioning CHRNA4’s role in nicotine me-
tabolism regulation. Considering the role of CHRNA4
in mediating nicotine’s effect as a receptor, it is tempt-
ing to hypothesize that it might play a novel role as
sensor in recognizing nicotine during its metabolism
in liver (Fig. 5d). Although some evidence has sug-
gested that individuals with reduced metabolic func-
tion of CYP2A6 smoke fewer cigarettes and have a
shorter smoking duration [35], the functionality of
CHRNA4 in both normal liver and hepatocellular
carcinoma still need to be further intensively
investigated.
Smoking behavior is associated with liver cancer [21].
However, the molecular mechanism underlying liver
cancer and the usage of tobacco, specifically nicotine
metabolism, remains a mystery. We found that the ex-
pression level of CHRNA4 and nicotine metabolism
genes, including CYP2A6, FMO3, UGT2B7 were dramat-
ically down-regulated in human hepatocellular carcin-
oma, suggesting disrupted nicotine metabolism in
hepatocellular carcinoma. Interestingly, CHRNA4 ex-
pression was low in matched normal liver cells from pa-
tients with cancer. Our analysis put HNF4A upstream of
liver-specific expression of both CHRNA4 and CYP2A6,
providing a potential mechanistic link between nicotine
receptor and nicotine metabolism. HNF4A could be a
key factor connecting nicotine metabolism and liver can-
cer. Previous studies showed that HNF4A was drama-
tically down-regulated or impaired in hepatocellular
carcinoma [36, 37], and that forced expression of
HNF4A in hepatocellular carcinoma cells could promote
the transition of tumors towards a less invasive pheno-
type [38, 39]. Collectively, these findings suggest a po-
tential connection between nicotine metabolism and
Table 1 Transcription factor motif analysis of SNPs associated with CHRNA4 liver-specific expression.
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liver cancer. Understanding the molecular mechanism of
such a connection could facilitate the study of smoking-
associated hepatocellular carcinogenesis, and might shed
new lights on clinical therapy of smoking cessations and
liver cancer.
Conclusion
Nicotinic receptor genes are strongly associated with
smoking behavior and nicotine dependence, and they are
generally believed to be expressed specifically in the
brain. In this work, by applying integrative genomics
and comparative genomics, we described the expression
and epigenetic landscape of nicotinic receptor genes in
different non-neuronal human tissues. We found that
nicotinic receptor alpha-4 (CHRNA4) was highly
expressed in liver tissue, when comparing to brain and
other tissues. We discovered a tissue-specific usage of an
alternative CHRNA4 promoter in human brain and liver,
identifying a novel liver-specific transcription start site
of CHRNA4, located about 3.9 KB upstream of known
canonical RefSeq TSS. This tissue-specific, alternative
promoter usage pattern is conserved in mouse, suggest-
ing a dynamic but epigenetically conserved evolutionary
history of CHRNA4. We also found that the expression
level of CHRNA4 was highly correlated with nicotine
metabolism genes, and CHRNA4 was down-regulated in
both hepatocellular carcinoma and tumor-adjacent nor-
mal liver tissues. Our study indicated that the integrative
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Fig. 5 Correlated expression between CHRNA4 and CYP2A6. a The enriched Canonical Pathways of genes positively/negatively correlated with
CHRNA4 in 119 normal liver samples. b Expression Pearson correlation coefficient between CHRNA4 and nicotine-metabolism related genes. c
CHRNA4 and nicotine-metabolism related genes were significantly down-regulated in hepatocellular carcinoma compared to normal liver samples.
ANOVA was performed to detect statistical significance. d Module of correlation and regulation between CHRNA4 and CYP2A6 in human hepato-
cytes. CHRNA4 and CYP2A6 are co-regulated by HNF4A and RXRA. The CHRNA4 nicotinic receptor on the cell membrane may trigger downstream sig-
naling pathways to stimulate regulation of CYP2A6 and itself
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analysis of published data could reveal new directions in
investigating the molecular mechanisms in nicotine sens-
ing and metabolism in liver, and how disruption of these
processes may play a role in hepatocellular carcinogenesis.
Methods
Processing RNA-seq data of the Human Roadmap
Epigenome Project
Processed mRNA-seq datasets (aligned to human refer-
ence genome hg19) from 56 reference epigenomics were
obtained from Roadmap epigenomics project through data
portal (http://egg2.wustl.edu/roadmap/web_portal/). Ex-
pression of all nAChRs were isolated and visualized by
using the gplots package in the R environment (Ver 3.2.2).
Processing RNA-seq data from the TCGA project
Processed mRNA-seq datasets (level 3, ht-seq reads
count files) of 374 liver cancer samples and 50 cancer-
matched normal samples were downloaded from the
Genomic Data Commons Data Portal (https://gdc-por-
tal.nci.nih.gov/). The RPKM of each gene was calculated
based on the annotated human gene length (GENCODE
V23).
Processing RNA-seq data from the GTEx project
Processed mRNA-seq datasets (version V6, Reads Per
Kilobase of transcript per Million mapped reads (RPKM)
of genes) and data description files of 8555 samples were
downloaded from the GTEx Portal (http://www.gtexpor-
tal.org/), including 119 liver samples, 320 lung samples,
149 colon sigmoid samples, 88 small intestine samples,
and 1259 brain samples. Genes expression levels in dif-
ferent tissues (brain, liver, colon, small intestine, lung,
and others) were plotted by using the ggplot2 package
in the R environment.
Co-expression correlation calculation
One-hundred nineteen human liver transcriptomes in
GTEx V6 data were used to calculate the co-expression
correlation between CHRNA4 and other genes. Genes
with an averaged expression level less than 1 RPKM
were filtered out. The Pearson correlation coefficient be-
tween CHRNA4 and all other genes was calculated by
using log-transformed RPKM with the cor function, and
p-values were calculated using the cor.test function in
the R environment. p-values were further corrected
using the p.adjust function with the BH method in R.
Only the genes with an adjusted p-value less than 0.01
were considered as significantly correlated to CHRNA4,
and were used to perform Ingenuity Pathway Analysis.
Ingenuity pathway analysis (IPA)
IPA (Ingenuity Systems, Redwood City, CA) software was
used to determine the functional pathways and regulatory
network models represented by the significantly correlated
genes. The gene set was imported into IPA to perform a
Core Analysis. The top 15 enriched canonical pathways
were selected based on significance (p-value < 0.05 ).
ChIP-seq data preprocessing and peak calling
The raw reads of RXRA and HNF4A ChIP-seq data were
downloaded from GEO, and aligned to the human gen-
ome (assembly hg19) and mouse genome (assembly
mm9) using Bowtie V1.0.0 [40]. methylQA was used to
process aligned bam files, isolate the non-redundant,
uniquely aligned reads only, and extend the DNA frag-
ments to 150 bp [41]. Additional file 8: Table S2 summa-
rizes the information for the individual ChIP-seq data
sample files used in this study.
The histone ChIP-seq data for human tissues (liver,
brain, lung, colon and CD34-HSC) were obtained from
the Roadmap Epigenomics Project through a data portal
(http://egg2.wustl.edu/roadmap/web_portal/). Raw-reads
were aligned to human genome (assembly hg19) and
mouse genome (assembly mm9) by using Bowtie V1.0.0
[40]. methylQA was used to process aligned bam files,
isolate the non-redundant, uniquely aligned reads only,
and extend the DNA fragments to 150 bp [41].
The histone ChIP-seq data for mouse liver and cortex
were obtained from the ENOCDE project through a data
portal (https://www.encodeproject.org.). Raw-reads were
aligned to the mouse genome (assembly mm9) using Bow-
tie V1.0.0 [40]. methylQA was used to process aligned
bam files, isolate the non-redundant, uniquely aligned
reads only, and extend the DNA fragments to 150 bp [41].
The MACSv2.0.10 [42] peak caller was used to compare
ChIP-seq signal to a corresponding ChIP-seq input con-
trol. To identify narrow regions of transcription factor/his-
tone enrichment (peaks) across the genome, a q-value
threshold of 0.01 was used. The bedGraph transcription
factor ChIP-seq data files and histone ChIP-seq data files
were visualized on the WashU Epigenome Browser.
FANTOM5 CAGE data processing
Cap Analysis Gene Expression by sequencing (CAGE-seq)
data (bam files, liver and brain tissues for both human and
mouse) generated by the FANTOM5 consortium were
downloaded from FANTOM FTP (http://fantom.gsc.ri-
ken.jp/5/datafiles/latest). The bam files were then converted
to a fastq file format, and aligned to human genome (as-
sembly hg19) and mouse genome (assembly mm9) using
Bowtie V1.0.0 [40]. The uniquely aligned reads were iso-
lated using Samtools, and further transformed into bed files
for visualization on the WashU Epigenome Browser.
DNA methylation data processing
Methylation calls for each CpG site were calculated
using Whole-Genome Bisulfite Sequencing (WGBS) data
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for human tissues (liver, brain, lung, colon and CD34-
HSC) obtained from the Roadmap Epigenomics Project
through a data portal (http://egg2.wustl.edu/roadmap/
web_portal/), and were visualized on the WashU Epige-
nome Browser. To measure the DNA methylation level
of CHRNA4 promoters, methylation of CpG sites with a
minimum of 10× coverage per site in a 1 KB region
around the CHRNA4 TSS in human liver, brain, and
CD34-HSC were isolated to generate boxplots and cal-
culate statistical significance.
eQTL data processing
Tissue-specific eQTL data were downloaded from the
GTEx Portal (http://www.gtexportal.org/). The SNPs lo-
cated in CHRNA4 loci and associated with CHRNA4
(ENSG00000101204.11) in human liver and hippocam-
pus were isolated using an in-house python script. The
p-value of each SNP was negatively log-transformed and
visualized on the WashU Epigenome Browser.
Motif analysis
Motif analyses were performed using the FIMO tool
from the MEME suite [43]. The 10 bp upstream and
downstream each SNP were isolated using bedtools (get-
fasta) from the human reference genome (assembly
hg19). Two allele-specific 21 bp DNA sequences were
generated based on the allelic information obtained from
dbSNP (build 144). Fimo was used to predict potential
TF binding sites in two allele-specific 21 bp DNA se-
quences by using a PWM of 519 transcription factors
downloaded from the JASPAR database [44].
Genome alignment
A genome alignment generated by blastz between hu-
man (hg19) and mouse (mm9) was obtained from the
UCSC genome browser (http://hgdownload.cse.ucsc.edu/
downloads.html), and then visualized on the WashU
Epigenome Browser to indicate the genome-level conser-
vation at the CHRNA4/Chran4 loci. Multiple alignments
of 45 vertebrate genomes of CHRNA4 promoters were
directly generated by UCSC genome browser (http://
hgdownload.cse.ucsc.edu/).
Quantitative real time PCR (qRT-PCR) analysis
The qRT-PCR analyses were performed using the Super-
Script VILO cDNA Synthesis Kit (Life Technologies)
with iTaq Universal SYBR Green Supermix (Bio-Rad).
All mouse and human brain and liver RNA was pur-
chased from ZYAGEN. 500 ng total RNA was used in a
20ul reverse transcription reaction. The cDNA obtained
was diluted to a total volume of 100ul and stored at
−20 °C. The primers for human CHRNA4 and mouse
Chrna4 (listed in Additional file 8: Table S3) were syn-
thesized by Integrated DNA Technologies. The qRT-
PCR was performed in a 20ul reaction mixture consist-
ing of 2ul diluted cDNA, 0.2uM of each primer, and
10ul iTaq Universal SYBR Green Supermix. All amplifi-
cations were carried out in a Bio-Rad CFX96 Real-Time
PCR Detection (Bio-Rad) with denaturation at 95 °C for
30s, followed by 40 cycles at 95 °C for 5 s and 60 °C for
30s. A melting curve analysis was performed for each
run to confirm the specificity of amplification and lack
of primer dimers. The qRT-PCR experiments were al-
ways run in triplicate. The relative mRNA expression
levels of target genes were quantified using the 2-ΔΔCT
methods as reported [45].
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